Halyard Health (NYSE:HYH) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Sunday.

Several other research firms have also weighed in on HYH. Zacks Investment Research raised shares of Halyard Health from a “sell” rating to a “hold” rating in a report on Thursday, October 19th. TheStreet lowered shares of Halyard Health from a “b-” rating to a “c+” rating in a report on Monday, October 30th. Stifel Nicolaus reaffirmed a “buy” rating and set a $45.00 target price on shares of Halyard Health in a report on Thursday, September 21st. Finally, KeyCorp reaffirmed a “hold” rating on shares of Halyard Health in a report on Tuesday, October 17th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $46.25.

Shares of Halyard Health (HYH) opened at $46.18 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.19 and a current ratio of 2.13. Halyard Health has a 12 month low of $35.24 and a 12 month high of $50.99. The company has a market cap of $2,162.91, a P/E ratio of 38.81, a price-to-earnings-growth ratio of 2.49 and a beta of 1.77.

Halyard Health (NYSE:HYH) last announced its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.60 EPS for the quarter, beating the consensus estimate of $0.47 by $0.13. Halyard Health had a net margin of 3.52% and a return on equity of 8.65%. The business had revenue of $401.40 million during the quarter, compared to analysts’ expectations of $394.54 million. During the same period in the previous year, the business posted $0.48 EPS. The business’s quarterly revenue was up 1.0% compared to the same quarter last year. equities research analysts predict that Halyard Health will post 2.08 earnings per share for the current year.

Large investors have recently bought and sold shares of the company. Amalgamated Bank increased its holdings in Halyard Health by 1.2% in the 2nd quarter. Amalgamated Bank now owns 6,655 shares of the medical instruments supplier’s stock worth $261,000 after acquiring an additional 82 shares in the last quarter. ETRADE Capital Management LLC increased its holdings in Halyard Health by 4.2% in the 2nd quarter. ETRADE Capital Management LLC now owns 9,671 shares of the medical instruments supplier’s stock worth $380,000 after acquiring an additional 390 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Halyard Health by 0.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 102,917 shares of the medical instruments supplier’s stock worth $4,042,000 after acquiring an additional 575 shares in the last quarter. Thrivent Financial For Lutherans increased its holdings in Halyard Health by 7.3% in the 2nd quarter. Thrivent Financial For Lutherans now owns 9,497 shares of the medical instruments supplier’s stock worth $373,000 after acquiring an additional 650 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in Halyard Health by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 4,732 shares of the medical instruments supplier’s stock worth $186,000 after acquiring an additional 711 shares in the last quarter. 89.71% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Halyard Health (HYH) Stock Rating Upgraded by ValuEngine” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.watchlistnews.com/halyard-health-hyh-stock-rating-upgraded-by-valuengine/1791852.html.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Analyst Recommendations for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.